The role of early invasive, selective invasive, or conservative strategies in acute coronary syndromes 58 rupture or erosion of an unstable atherosclerotic plaque. Rapid restoration of fl ow in the infarct-related coronary artery is of paramount importance to limit the infarct size. Thus primary PCI has become the standard of care in appropriate settings and defi nitive goals have been set in the form of Door-to-Balloon time of less than 90 minutes for primary PCI and Door-to-Needle time of less than 60 minutes for fi brinolytic therapy.
INTRODUCTION
Acute Coronary Syndrome (ACS) comprises three related disorders:
ST-elevation myocardial infarction (STEMI), unstable angina (UA), and non-ST-elevation myocardial infarction (NSTEMI). The initial management of STEMI differs considerably from that of UA and NSTEMI, which is generally considered as one clinical entity (UA/NSTEMI). STEMI, which is responsible for 25% of ACS cases, occurs as a result of total occlusion of an epicardial coronary artery by an intra-luminal thrombus after 59 Vol. 5, No. 2, 2008 strategy in which patients, after appropriate medical stabilization, undergo coronary angiography and revascularization only if there is evidence of recurrent ischemia, e.g. recurrent infarction, angina at rest, dynamic ST-segment changes on ECG or inducible ischemia. Two alternatives for the invasive approach have emerged: early ("immediate") or deferred angiography, i.e. after a 12 to 48-hour window from symptom onset.
The choice of strategies has led to many debates at conferences and in the literature and there is widespread variation in procedure use among individual clinicians, institutions and countries. (2) Proponents of the early invasive strategy argue that the early determination of coronary anatomy can be used to tailor therapy, avoid lengthy hospital stay and prevent further ischemic events. Proponents of the conservative strategy argue that medical therapy can stabilize patients and that noninvasive testing can identify patients at risk of future events and thus identify patients who would most benefi t from invasive intervention.
Thereby, the costs and complications of invasive procedures can be minimized by using these modalities selectively. The last argument is particularly relevant to our own practice environment in South Africa, where resources are limited, especially in the public sector. Over the last decade many randomized trials and large scale registries have been published on this topic. The evidence for the relative benefi t or harm of these two approaches, as well as patient selection for the respective strategies and optimal timing for coronary angiography is the subject of this review.
CHOICE OF STRATEGY
A meta-analysis of seven randomized trials (including early studies prior to the widespread use of stents and multi-drug adjunctive therapy) 14.0%) and a 34% reduction in rehospitalization (32.5% vs. 41.3%) in patients who were stratifi ed to the early invasive strategy.
A clue to risk stratifi cation was provided by the biomarker data. Higher risk patients with elevated cardiac biomarkers at baseline benefi ted more from early invasive intervention, with no signifi cant benefi t observed in lower-risk patients with negative baseline biomarker levels.
The ICTUS trial (4) was not included in the meta-analysis, as its results 
The primary composite endpoint was 30% in the early invasive group and 26% in the selective invasive group (p=0.09). No difference in overall cardiovascular mortality was noted between early invasive and selective invasive strategies (4.5% vs 5.0% p=0.97).
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The discrepancy between the ICTUS study and the results of the Mehta meta-analysis could, in part, be attributed to the relatively high rates of revascularization in the two study groups of the ICTUS trial (76% in the invasive and 40% in the selective invasive group). (4) Another factor could be that all patients in the ICTUS study received intensive medical therapy.
One of the weaknesses cited of the meta-analysis by Mehta et al. was that many of the trials included in the analysis were not contemporary to current clinical practice. In four of the trials, namely TIMI-3B, (6) VANQWISH. (7) MATE, (8) and FRISC-2, The most recent meta-analysis published on the subject included 7 studies comprising 8 375 patients. (11) These studies refl ect contemporary practice in that all patients received aspirin, unfractionated or low molecular weight heparin. Glycoprotein IIb/IlIa inhibitors were available during PCI in 6 of the 7 trials and thienopyridines were used as an adjunct to PCI in all trials. For the primary outcome of all-cause mortality at a mean follow-up of 2 years there was a signifi cant risk reduction for all-cause mortality from 6.5% for the conservative strategy to 4.9% for an early invasive strategy (RR, 0.75; p=0.001),
without an excess of early death (Figure 1) . The analysis of all-cause mortality showed no heterogeneity between studies. Interestingly the analysis of mortality demonstrated that with longer follow-up, the mortality benefi t increased. Thus the risk reduction at 1 month was 18%, at 6 months 17%, at 12 months 20% and at 2 years 25%.
Furthermore, the incidence of non-fatal MI at 2-year follow-up was lower with the early invasive versus the conservative approach (7.6% vs. 9.1% p=0.012) again without an excess of early non-fatal MI (Figure 2 ). Long-term mortality reduction has further been confi rmed in the 5-year follow-up data of the RITA-3 (12) trial and the 2-year followup data of the FRISC-2 trial. (9) However, it must be noted that the longterm follow-up at 3 years of the ICTUS study showed no mortality difference between the two treatment strategies. 
Favours Conservative therapy
Based on the above evidence, it is reasonable to conclude that in patients with UA/NSTEMI, a routine early invasive strategy is preferable to a selective invasive strategy in reducing major adverse cardiovascular events as well as severe angina and rehospitalization. However, it appears that the major benefi t of an early invasive strategy resides in reducing cardiovascular events over the long term with the risk that this strategy may be associated with an early hazard of myocardial infarction.
Therefore, future strategies should focus on ways of reducing the early hazard and enhancing the later benefi ts of a routine invasive strategy.
It is also important to note that in almost all the randomized trials, a signifi cant proportion of patients in the conservative arm eventually underwent revascularization ("crossover"), such that the benefi t of revascularization may have been underestimated. (10) 
TIMING OF INVASIVENESS
With the exception of indications for emergency / urgent angiography and revascularization, controversy remains as to the optimal timing between hospital admission, initiation of medical therapy, and the invasive evaluation.
Support for immediate angiography comes from the ISAR-COOL trial. (13) In this trial, 410 consecutive, high-risk NSTEMI patients were treated with intensive medical therapy; including aspirin, heparin, clopidogrel (600mg loading dose), and the Glycoprotein IIb/IlIa inhibitor, tirofi ban. Patients were randomized to immediate angiography (on average 2.4 hours after admission) or delayed angiography after a prolonged "cooling off " period before catheterization (86 hours after admission and medical therapy). Patients randomized to immediate PCI had a lower incidence of death or MI at 30 days than patients randomized to deferred PCI (5.9% vs. 11.6% p=0.04). Likewise, no early hazard was observed in the TACTICS-TIMI-18 study wherein patients were treated with upstream Glycoprotein IIb/IlIa inhibitor and where the mean delay to PCI was 22 hours. (14) At variance with these fi ndings, are the results of the ICTUS trial, which showed that early routine invasive strategy within 48 hours after randomization was associated with an excess of MI. (4) Expedited catheterization was also associated with worse outcome in the FRISC-2 (9) study as well as in the CRUSADE registry. (15) Accordingly, current data does not mandate a systematic approach of immediate angiography in UA/NSTEMI patients stabilized with contemporary medical therapy. Both the ESC (1) and ACC/AHA (16) guidelines for the management of patients with UA/NSTEMI suggest that angiography / revascularization can be performed safely within 4 to 72 hours of admission provided the patient is stabilized with optimal medical therapy.
SELECTION OF THE INITIAL TREATMENT STRATEGY BASED ON RISK FACTORS
The primary objective in selecting a treatment strategy in UA/NSTEMI is to yield the best long-term clinical outcome. In the individual patient the risk or hazard of an early invasive angiography / revascularization should be weighed against the long-term benefi t accrued from such a strategy. Risk stratifi cation is an integral component of managing patients presenting with UA/NSTEMI. The goal of risk stratifi cation is to identify patients with a high likelihood of an early complicated outcome who are at risk of recurrent coronary events or premature death and to offer such patients the benefi t of early angiography and revascularization.
Patients presenting with persistent or recurrent ischemia, hemodynamic or electrical instability, or heart failure have a particularly high risk for major adverse cardiovascular events, and therefore benefi t from urgent angiography with revascularization (PCI or CABG).
The current guidelines (1, 16) recommend the use of several parameters for risk stratifi cation for patients presenting with UA/NSTEMI, e.g. the TIMI (17) risk score (Table 1) or GRACE (18) risk score (Table 2 ). Patients presenting with moderate to high risk features according to one of these scoring systems also attain signifi cant benefi t from an early /
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routine invasive strategy. The recently published guidelines (1) emphasize that patients with characteristics as listed in Table 3 , be classifi ed as intermediate to high risk for major adverse cardiovascular events in the foreseeable future and should be submitted to an early invasive strategy.
Coronary angiography, by its very nature, risk stratifi es patients. Not only does it defi ne the degree and extent of coronary artery disease and thus the risk for recurrent events or mortality; but it is also a way of determining left ventricular function which in itself is a strong predictor of outcome in a wide spectrum of patients. Angiography is therefore clearly an important tool in the clinical decision making of patients with ACS. On the other end of the spectrum is the low risk patient group in whom an early invasive strategy may be detrimental. This group of patients is equally well served with a conservative strategy or an elective angiography / revascularization should they have high risk features on non-invasive testing.
CONCLUSION
There is sound evidence-based data that patients presenting with UA/NSTEMI, with the exception of the low risk group, will benefi t from NSTEMI. In the conservative arm of the study, 94% of patients were on statin therapy and 50% on clopidogrel at the time of discharge. Both these agents have been shown to reduce cardiac events in the management of UA/NSTEMI. It has been suggested that the neutral outcome of the ICTUS trial was related to the very high rates of optimal medical therapy in the two groups of patients. (19) Future research needs to clarify the optimal timing of the invasive approach and to determine additional strategies for minimizing the early hazard of angiography. Research also needs to ascertain whether additional risk stratifi cation will help in determining the best approach to an individual patient with UA/NSTEMI. 
